Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Elisabetta Perrone

9PUBLICATIONS

11CO-AUTHORS

Radiation therapyCancer therapy (excl. chemotherapy and radiation therapy)Pharmaceutical delivery technologiesSolid tumoursPharmacogenomics

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (9)

Sort by Publication Date:

|Apr 01, 2026

First-in-Human Combination of Lead-212-Labeled PSMA Radioligand Therapy and Metabotropic Glutamate Receptor Inhibitor Riluzole as Radiosensitizer in Metastatic Castration-resistant Prostate Cancer.

Elisabetta Perrone, Lukas Greifenstein, Kriti Ghai

|Nov 27, 2025

First Autopsy-confirmed Complete Remission of Metastatic Neuroendocrine Neoplasm of Tailgut Cyst After a Single Cycle of Alpha-Peptide Receptor Radionuclide Therapy With [ 225 Ac]Ac-DOTA-LM3.

Elisabetta Perrone, Shagufta Shaheen, Pamela L Kunz

|Sep 27, 2025

Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in Patients with Neuroendocrine Neoplasm: A Retrospective Study Concerning Safety and Survival.

Elisabetta Perrone, Maria Lucia Calcagni, Lucia Leccisotti

|Jul 29, 2025

In Vivo Versus In Vitro Somatostatin Receptor Expression in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis of Correlation Studies.

Elisabetta Perrone, Giorgio Treglia, Romina Grazia Giancipoli

|Mar 07, 2025

TANDEM Peptide Receptor Radionuclide Therapy Using [ 225 Ac]Ac-/[ 177 Lu]Lu-DOTA-LM3 in a Patient With Parotid Gland Metastasis From Pancreatic Neuroendocrine Neoplasm.

Elisabetta Perrone, Kriti Ghai, Aleksandr Eismant

|Feb 25, 2025

Axillary Skin Fibroblast Activation Protein Uptake After Chemo-immunotherapy on PET/CT and SPET/CT: A Mere Coincidence or Causality?

Elisabetta Perrone, Kriti Ghai, Aleksandr Eismant

Pageof 2

Frequent Collaborators

4 joint publications

Richard Paul Baum

3 joint publications

Aleksandr Eismant

3 joint publications

Lucia Leccisotti

3 joint publications

Tanay Parkar

1 joint publications

Mikkel Andreassen

1 joint publications

Andreas Kjaer

1 joint publications

Kriti Ghai

1 joint publications

Jörg Müller

1 joint publications

Giorgio Treglia

1 joint publications

Guido Rindi

Frequent Collaborators

4 joint publications

Richard Paul Baum

3 joint publications

Aleksandr Eismant

3 joint publications

Lucia Leccisotti

3 joint publications

Tanay Parkar

Top Related Videos

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on : Apr 24, 2020

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on : May 24, 2024

See more related videos

Top Related Videos

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on : Apr 24, 2020

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on : May 24, 2024

See more related videos